Tenaya Therapeutics (TNYA) provided an update on its clinical development programs and outlined its strategic priorities for 2025. Updates: Continued Focus on Driving Advancement of TN-201 and TN-401 Gene Therapies for Cardiomyopathies; Dosing Initiated in Cohort 2 of the MyPEAK-1 Phase 1b/2 Clinical Trial of TN-201 for Treatment of MYBPC3-Associated Hypertrophic Cardiomyopathy; Additional Cohort 1 Data to be Reported in 1H25 Building on Promising Initial Data; Initial Data from RIDGE-1 Phase 1b Clinical Trial of TN-401 for PKP2-Associated Arrhythmogenic Right Ventricular Cardiomyopathy Expected in 2H25
Stay Ahead of the Market:
- Discover outperforming stocks and invest smarter with Top Smart Score Stocks
- Filter, analyze, and streamline your search for investment opportunities using Tipranks' Stock Screener
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on TNYA:
- Largest borrow rate increases among liquid names
- Tenaya Therapeutics price target lowered to $6 from $8 at Leerink
- Piper bullish on Tenaya, says initial MyPEAK-1 data de-risks higher dosing
- Tenaya Therapeutics Reports Promising TN-201 Trial Results
- Tenaya Therapeutics’ Senior VP Resigns for New Opportunity